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Abstract

THE EFFECT OF CELL-TYPE ON THE EFFICACY OF CMV ANTIVIRAL DRUGS
By Benjamin Meza, MS
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University.

Virginia Commonwealth University, August 2008

Major Director: Michael McVoy, Ph.D.
Professor, Department of Microbiology and Immunology

Until recently, all in vitro drug susceptibility assays of cytomegalovirus (CMV)
were performed in clinically irrelevant fibroblast cells. This study sought to test if drug
susceptibility was affected by cell type. MRC-5 embryonic lung fibroblasts and ARPE-19
retinal pigmented epithelial cells were infected with BADrUL131-Y4 epithelial/fibroblast
tropic virus under serial concentrations of ganciclovir (GCV) or maribavir (MBV). Virus
was quantified using plaque reduction, GFP fluorescence, and yield reduction. Both drugs
performed less efficiently in ARPE-19 cells. A cell type effect was observed for both
plaque reduction and yield reduction assays with implications for the treatment of CMV
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retinitis as well as other manifestations of CMV Disease that involve non-fibroblast cell
types.

Chapter 1: Virus and Host
Human cytomegalovirus (CMV) accounts for one of the most significant infectious
causes of birth abnormalities in the developed world and is an important pathogen for
immunocompromised individuals such as AIDS patients and allogeneic transplant
recipients. In immunocompetent adults, the virus is poorly pathogenic. Primary infection
may be asymptomatic or produce mild cold-like symptoms, progressing to a latent
infection (108). Like others in the betaherpes subfamily, CMV can persist for the lifespan
of its host, using sophistocated means of evading the host immune system, replicating, and
laying dormant. As such, epidemiological studies report from 40-80% of the US adult
population are seropositive (68). One study of US residents six years and older tested for
anti-CMV IgG and found the population's overall seroprevalence between 1988-1994 to be
58.9%. Naturally, seroprevalence increased with age and correlated strongly with markers
of socioeconomic status, such as household income, education level, race/ethnicity, and
type of medical insurance (105). Concurrently, some research has found seroprevalence
rates greater than 90% among homosexual men, poor-socioeconomic groups, and residents
of developing countries (106).
The virus’s victims fall into three major categories of immunologically
compromised patients: infants in the case of congenital or perinatal infection, AIDS
patients, and allogeneic transplant recipients. All three of these populations lack a fully
1
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functioning immune system and thus are at risk of becoming newly infected or reactivating
latent virus.

1.1 Congenital & Perinatal CMV
A child can acquire CMV in utero, during delivery, from post natal blood
transfusion, or from infected secretions such as saliva or breast milk. These routes are
commonly classified into two categories: "congenital" if virus is isolated within three
weeks of age and "perinatal" if isolated between three weeks and 12 months (109). This
distinction is important in predicting probable sequelae. Furthermore, the outcomes of
congenital CMV infection depend on whether it results from a primary or non-primary
maternal infection.
Worldwide, up to 2.3% of all live births will present with congenital CMV
infection as detected by urine polymerase chain reaction (95). While all geographic regions
and socioeconomic classes are at risk, there are higher rates of incidence among dense
populations and poor demographics (28). In the United States, congenital CMV affects
approximately 1% of all live births each year, making it the most common congenital
infection and a major cause of morbidity and mortality among infants. While the majority
of these children will suffer from no serious pathologies from the virus, approximately
10% will be symptomatic at birth and another 10-15% who are asymptomatic at birth will
experience sensorineural hearing loss or developmental problems during childhood (68).
Mortality among symptomatic neonates may be as high as 30% and more than 90% of
survivors will show signs of hearing loss, mental retardation, delay in psychomotor

3
development, or optic atrophy (62). In the US healthcare system, physical examination of
newborns includes identifying signs of TORCH infections. TORCH is an acronym for
some of the most common perinatal infections: toxoplasmosis, other (i.e. syphilis, human
parvovirus, listeria, Coxsackie virus, etc.), rubella, cytomegalovirus, and herpesviruses (i.e.
herpes simplex, Epstein-Barr virus, Varicella-zoster virus, etc). Of these agents, which
often cause malformations and cognitive retardation, CMV is the most common (26).
Some of the malformations associated with CMV include microcephaly, cerebral
calcifications, chorioretinitis and blindness, and hepatosplenomegaly (26).
Congenital cytomegalovirus is transmitted through the placenta to the fetus via
maternal infected leukocytes. Replicating in placental fibroblasts, syncytiotrophoblasts and
cytotrophoblast cells, the virus moves through the umbilical cord, ultimately to be taken up
by the fetal circulation (109). These same infected cells can be shed into the amniotic fluid
that is swallowed by the fetus. An infected oropharynx and colonization of the
gastrointestinal and genitourinary tracts result (28).
Though transmission from mother to child can occur throughout the entire
pregnancy and during or after delivery, route of transmission and clinical outcome depend
on both the timing of infection and sero-status of the mother. Intrauterine infection occurs
in approximately 50% of primary maternal infections. In contrast, non-primary maternal
infections make up only 3.2% of all congenital CMV infections (109). A study by Pass et
al. showed that children born to mothers who contracted a primary CMV infection during
their first trimester had a higher frequency of central nervous system (CNS) sequelae than
did those born to mothers who contracted the virus later in gestation. The sequelae were
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also much more severe in the latter group, consisting of mental retardation, cerebral palsy,
seizures, chorioretinitis, and, especially, sensorineural hearing loss (83).
Perinatal infections are more common than congenital infections but symptoms
tend to be less severe. In these cases, the virus may be contracted during parturition from
infected cervical tissue or after birth from infected breast milk, a blood transfusion,
fomites, and contact with other children. Ninety percent of infants presenting viremia will
be asymptomatic. The other 10% who are symptomatic may have encephalitis,
gastroenterological disorders, hepatitis, pneumonitis, splenomegaly, or thrombocytopaenia
(109).
The differences between the congenital and perinatal prognosis necessitate
screening for the disease within three weeks of age. The standard of practice for these
screens is a urinary CMV polymerase chain reaction (PCR), which detects viral DNA in
the urine. PCR can also be performed on saliva and amniotic fluid but sensitivity is highest
in the urine (28).
Treatment of perinatal and congenital CMV infections is controversial, due in part
to the lack of treatment options and because of the severe side effects of available
treatments. Ganciclovir (GCV) is the only antiviral drug that has undergone extensive
clinical trials in infants and neonates. One study conducted by the National Institute of
Allergy and Infectious Diseases collaborative Antiviral Study Group (CASG) looked at the
effect of GCV treatment on symptomatic congenital CMV infection with central nervous
system (CNS) involvement (116). Parenteral treatment was carried out every 12 hours over
a period of six weeks and, as expected from such a long period, most of the infants

5
suffered some degree of thrombocytopenia and neutropenia attributed to GCV.
Nevertheless, the study found that at a six month follow-up, five of 30 babies (16%)
showed hearing improvement or stabilization. Subsequently, a Phase III randomized
controlled study of parenteral GCV treatment in neonates with symptomatic congenital
CMV infection involving the CNS also found promising results (53). Neonates were
treated every 12 hours for six weeks. At a six month follow-up, 84% of the treated group
showed an improvement in hearing or maintenance of normal hearing, as compared to only
59% of the placebo group. Furthermore, none of the GCV group showed deterioration,
whereas 41% of the placebo group suffered from a deterioration in hearing. At 12 months,
68% of the placebo group showed signs of worsening hearing, compared to only 21% of
the GCV treated group. Again, most of the neonates (63%) had significant neutropenia. In
both of these studies, a transient drop in CMV shedding at mucosal sites was detected yet
upon termination of therapy, excretion inevitably resumed.
Data on the efficacy of other therapies in congenitally or perinatally infected
individuals is limited. CMV hyperimmunoglobulin (CMV-Ig), which is concentrated
plasma antibodies from individuals who have high anti-CMV ELISA titers, is in use
among adults and in pregnant mothers who contract a primay CMV infection in their first
trimester. There are a number of studies which have suggested that while CMV-Ig cannot
prevent infection, it can prevent serious CMV disease (78, 79). Cases where congenitally
infected infants were treated with other antiviral drugs, such as Cidofovir (CDV) and
Foscarnet (FOS), appear in the literature but pose even greater side effects than GCV. In
this situation, an ethical dilemma arises. To use these drugs as prophylaxis would be
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unethical due to their highly toxic nature and potential as teratogens. Yet CMV disease
can be just as devastating. Children who are symptomatic at birth would probably benefit
from drug treatment but will always be a subset of children who are not symptomatic at
birth but who will still develop neurological disorders associated with CMV disease.

1.2 CMV Infection and Disease among Transplant Recipients
Immunocompromised individuals are also at high risk for CMV infection. In fact,
the severity of the disease is correlated with the degree of immunosuppression. Bone
marrow transplant recipients and AIDS patients with very low CD4+ T-cell counts have
the most severe disease. Solid organ transplant recipients, patients under an
immunosuppressive chemotherapy regime, and subjects with other immunodeficiencies
also suffer from CMV disease, though clinical diseases are predominant in each group
(61).
In their 1998 review of organ transplant infections, Fishman and Rubin delineate
two factors that determine the risk of infection after organ transplantation: epidemiologic
exposure to pathogens and the recipient’s net state of immunosuppression (31). The
highest risk of infection comes from CMV, which newly arises or reactivates from latency
in up to 75% of solid organ transplant recipients (SOT) (32). Risk of infection is highest
among seronegative recipients who receive tissue or organs from seropositive donors
(D+/R-). These individuals have infection rates upwards of 20 times higher than R-/Dindividuals as determined by the number of individuals with primary or reactivated disease
within one year of transplantation. Rates of infection among R+/D- and R+/D+ transplants
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fall somewhere within this interval. It should be noted that 5% of D-/R- patients will also
become infected as a result of blood transfusions, improper serological testing, and other
inaccuracies (32). An individual's level of immunosuppression is contingent on a number
of interrelated factors, including, but not limited to, immunosuppressive therapy (dose,
time course of different drugs), presence of other immunomodulatory parasites (e.g.,
CMV, Epstein-Barr virus, Hepatitis B and C, human immunodeficiency virus), and any
corporal outcomes associated with the procedure itself (e.g., injured tissue) (31). Other
risk factors include: donor’s age, recurrent rejection, HLA mismatches, hypertension,
hypercholesterolemia (107).
CMV infection is distinguished from CMV disease. Both indicate the presence of
viremia but the former is asymptomatic while the latter presents symptoms. An example of
CMV infection without disease might be an individual who underwent SOT two years
earlier and who is still moderately immunosuppressed. If the individual’s immune system
is able to suppress viral replication but is unable to eliminate cells which harbor the virus,
PCR will detect viral DNA in the blood absent clinical manifestations of disease (66). The
effects of CMV infection and disease can be divided into those that are direct and those
that are indirect. Direct disease may be subdivided into CMV syndrome, which resembles
mononuclosis- or flu-like symptoms (often with neutropenia), and tissue invasive disease
presented as pneumonitis, gastrointestinal disease, hepatitis or retinitis (32). The indirect
effects of active CMV infection appear to be much more complex. As CMV is an
immunosuppressive virus, infection has been implicated in increased risk of bacterial,
fungal, and other viral infections such as human herpesvirus 6 and 7 (HHV-6 and HHV-7)
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Epstein Barr virus (EBV), and hepatitis C. Furthermore, coinfection with Epstein-Barr
virus, an oncogenic gammaherpes virus, is associated with higher risk of post-transplant
lymphoproliferative disease in patients with CMV (66). CMV has also been implicated in
acute allograft rejection, graft loss, and chronic allograft rejection. Accelerated transplant
vascular sclerosis caused by an inflammatory response to the latently infected vasculature
may be a major contributor to these outcomes (107). Alloreactive T-cells may be a
contributing factor to endothelial damage (51).
Currently, prophylaxis, preemption, and treatment of CMV disease in SOT patients
centers around a handful of therapies including: GCV, CMV-Ig, foscarnet, and cidofovir.
Ganciclovir was the first antiviral drug found to be effective against CMV infection (24).
As it became available, rates of CMV mortality dropped and today they are a rare event
(32). Today the controversy is not what to use but how to use it. Prophylaxis with
ganciclovir and related drugs (i.e., acyclovir, valciclovir) significantly reduce the risk of
CMV infection and disease, mortality, and disease caused by other infectious agents (10,
40). In D+/R- kidney, heart and combination heart-lung transplants, ganciclovir
prophylaxis has been shown to effectively suppress viremia during the initial months of
infection and prevent the direct and indirect effects of disease. Patient mortality may also
be decreased. In contrast, prophylaxis has not found much support among other transplant
groups (e.g., D+/R+, D-/R+, D-/R-, liver transplant recipients) (81). For these patients, a
preemptive approach (i.e., treating after serum or leucocyte dectection of CMV DNA or
pp65 viral antigen but before symptoms appear) may be on par with prophylaxis (66). One
of the prevailing side effects of many anti-CMV drugs is neutropenia (42). In the case of
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ganciclovir and its derivatives, this may be due to inhibition of DNA polymerase in
hematopoietic progenitor cells (104). To counter this effect colony stimulating factors have
been used concomitantly with GCV, with relative success (7).

1.3 Coinfection with the Human Immunodeficiency Virus
Another major cause of immunosuppression and partner of CMV infection is
human immunodeficiency virus (HIV). The most common manifestation of CMV disease
in HIV seropositive individuals is retinitis, making up 85% of cases (106). In developing
nations, this pathology is the number one cause of visual loss in HIV-infected patients in
great measure because of the lack of highly active antiretroviral therapy (HAART) (52).
HAART is a novel approach of combining at least three antiretroviral drugs of different
classes in the treatment of HIV. Before the therapy’s introduction in the United States
around 1995, CMV was one of the most important opportunistic infections of HIV
sufferers, afflicting up to 40% of individuals with advanced HIV disease (106). New
approaches to HIV treatment in the developed world has lead to increased life-expectancy
and quality of life, with the suppression of HIV viraemia and concurrent reduced incidence
of CMV disease in this population. There are, however, subgroups of patients still at risk
for CMV disease. In particular, those HIV-infected individuals who have CD4+ T-cell
counts below the critical threshold of 100/mm3 are at increased risk for many opportunistic
infections such as CMV. As it requires up to eight months for HAART therapy to induce
that degree of reconstitution of cellular immunity in most patients, a vulnerable population
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arises (70). Additionally, a proportion of individuals are either non-adherent or do not
respond to HAART therapy (e.g., develop resistance).
Prior to the advent to HAART, about 30% of people living with AIDS would
develop retinitis (41). HAART has decreased this number by 75% (44). The retina is
isolated from the rest of the body by several ocular tissues including the outer blood-retinal
barrier, made up of the retinal pigment epithelium. These barriers block efficient drug
delivery for vitreoretinal diseases such as CMV retinitis. In the past, GCV was injected
into eyes to treat CMV-retinitis, however, this procedure is highly invasive and the
intravitreal half-life of GCV is only about 18 hours (73). Repeated intravitreal injections
often result in complications such as vitreous hemorrhage, endophthalmitis, and retinal
detachment (121). To overcome these barriers to drug delivery, intraocular controlled
(sustained)-release systems have been devised, using a number of different technologies,
including: drug infused liposomes (84), biodegradable microspheres (72), and implants
that are either non-biodegradeable (93) or biodegradable (38, 54). These devices can
effectively prevent retinal disease from becoming worse, but fall short of clearing the
virus.
CMV has also been implicated in the progression of HIV to AIDS. In one study of
290 patients who contracted HIV either through sexual intercourse, infected blood
products, or IV drug use, the researchers found that progression to AIDS was two-fold
more rapid among patients who became CMV seropositive. This increased risk of
progressing to AIDS, generated by a primary CMV infection, even affected patients with
relatively high CD4+ T-cell counts (>100/mm3) (91).

11
Ironically, effective therapies have also given rise to what is termed as immune
reconstitution inflammatory syndrome. In these cases, an unusually high incidence of
vitritis (inflammation of the eye chamber) has been recorded and is generally ascribed to
the reaction of the regenerating immune system to persisting viral antigens, in part from
CMV (106).

1.4 Microbiology of CMV
Cytomegalovirus is a member of the herpesviridae family. The family is made up
of eight herpes viruses known to infect humans. These viruses are then divided into three
subfamilies: alpha, beta, and gamma. Herpesviruses were originally classified into these
subfamilies according to their in vitro and in vivo biological properties, including: tissue
tropism in vivo, host cell range in vitro, and characteristics of in vitro infection (e.g.,
duration) (77). These classifications were later bolstered with the discovery of distinct
genomic similarities within subfamilies (77).
The alpha subfamily, characterized by latent neurotropism, includes human herpes
virus 1 (HHV-1) and 2 (HHV-2), more commonly known as herpes simplex types 1 and 2
respectively. This subfamily also includes varicella zoster virus, the virus that causes
chickenpox and shingles. In the gamma group of lymphotropic herpesviruses, one finds
Epstein-Barr virus (EBV) and KSHV. Both are potentially oncogenic and are associated
with posttransplant lymphoproliferative disease (PTLD) and Kaposi’s sarcoma,
respectively. Cytomegalovirus (also classified as HHV-5), along with HHV-6 and HHV-7
(which both can cause roseola infantum), are categorized as beta herpesviruses and as of
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yet do not have a single cell type of latent infection. Worthy of note, CMV is believed be
carried latently in cells of myeloid lineage (e.g., monocytes) as an episome (98).
In all herpesvirus genomes, there are a common collection of about 40 highly
conserved genes (17, 50), comprising 25-70% of the genes of a particular virus (67, 77). A
phylogenic analysis of herpesviruses undertaken by McGeoch et al. traces the coevolution
of these viruses and their hosts. According to their analysis, the three subfamilies may have
arisen up to 220 million years ago and began parallel speciation with their hosts probably
around the time of the mammalian radiation, 80 million years ago (67).
The CMV virion structure is much like other herpesviruses. A loose lipid bilayer,
studded with a large number of glycoproteins encircles the viral tegument, a proteinaceous
layer which itself surrounds the viral capsid. The icosahedral nucleocapsid is
approximately 100nm in diameter and encases the viral DNA. The entire virion is
approximately 150-200nm in diameter (61).
CMV has a double-stranded linear DNA genome of 230 kbp, the largest of any
herpesvirus. The genome contains a unique long (UL) and a unique short (US) region, each
flanked by repeat regions. The UL and US regions are able to isomerize such that the
genome can exist in four isomers: prototype, inverted L, inverted S, inverted L and S.
Isomerization of the UL and US regions is contingent on the direct repeat sequences found
at the genome termini and their inverted counterparts found at the UL-US junction (71).
Of the handful of laboratory-adapted strains of CMV, the study of two strains, originally
intended as live attenuated vaccine candidates: AD169 and Towne, tell us much about the
virus’ genome. Analysis of the AD169 genome has uncovered 225 open reading frames
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(ORF) coding some 213 unique proteins, whose functions are mostly unknown (61, 80).
Each reading frame is named according to its region and a number designating its relative
position (e.g., UL130, UL131, US32, US33, etc.). Other laboratory-adapted strains, such as
Towne and Toledo, contribute additional distinct ORFs.
Viral genes are grouped into three kinetic classes: immediate early (IE or ), early
(E or ), and late (L or ). These categories correspond to the temporal appearance of the
gene’s products. IE genes, for example, are defined as those genes whose expression does
not require the expression of other viral genes. Genes in this first kinetic class are often
responsible for activating the transcription of E genes. The second kinetic class, early
genes, does not require DNA synthesis but also cannot be expressed without the products
of IE genes. They are often involved in DNA synthesis. Late genes require DNA synthesis
and typically encode structural genes necessary to construct new viral progeny.

Chapter 2: Antiviral Drugs and Treatment
2.1 Cell-Type Tropism
At the crux of this paper’s argument is the issue of CMV cell tropism.
Immunohistochemical staining of autopsied tissues demonstrates the presence of CMV in a
variety of cell types including: endothelial cells, epithelial cells, smooth muscle cells,
mesenchymal cells, hepatocytes, monocytes/macrophages, and granulocytes. Ductal
epithelial cells are most commonly infected but, in disseminated infections, high
concentrations of CMV infected cells have been found in the lung, pancreas, kidneys, and
liver (3, 85).
In contrast, the in vitro biological properties of the virus have been studied almost
exclusively in clinically irrelevant fibroblasts. To a large extent, this inclination has been
driven by the convenience of laboratory-adapted strains of the virus that provide
controlled, reproducible results but preferentially infect fibroblasts. As mentioned before,
there are a handful of commonly used lab-adapted strains of CMV. Among them are
AD169 and Towne. Both strains were originally developed as potential live attenuated
vaccine candidates, both were serially passaged in fibroblast cells to reach high titers in
vitro (~107), and both suffered gross genetic mutations in the process. Upon isolation
from the adenoids of a 7-year-old girl undergoing tonsillectomy-adenoidectomy, AD169
was passaged over 50 times in fibroblast cells (88, 92). Towne has a similar history.
14
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Derived from the urine of a congenitally infected 2-month-old infant, the virus was
subsequently passaged over 125 times, including three endpoint dilutions (86, 88). In both
instances, the viruses underwent numerous point mutations and rearrangements (15, 88).
As a result of laboratory-adaptation, these two viruses and others like them replicate to
high titers in fibroblasts, but poorly in other cell types such as epithelial or endothelial
cells. Clinical isolates, however, replicate just as well in endothelial and epithelial cell
cultures as fibroblasts (61, 113).
Because CMV has such a large genome and most of its genes have yet to be
functionally characterized, associating biological and genetic differences between strains
can be very difficult (88). Yet stark differences in cell tropism have been traced back to
genetic alterations, which arise from serial passage of virus strains in fibroblast cell
cultures, and not just epigenetic phenomena (100). In 2004, Hahn et al. used knockout
mutants and trans-complementation to identify the UL131-128 locus as the primary
determinant of endothelial cell tropism. The locus contains two spliced mRNAs and three
ORFs: UL128, UL130, and UL131. A deleterious mutation in any one of these ORFs can
annul endothelial tropism (37). Such deleterious mutations have been found in both AD169
and Towne, which should not be surprising as it has been shown that as few as three
passages of a clinical isolate in fibroblast culture can abolish endothelial tropism (6). In
AD169, a single nucleotide insertion in the UL131 locus generates a frameshift and
truncation of the mRNA that UL131 encodes (27, 113). Town has a similar frameshift in
the UL130 locus (74).
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In 2005, Dai Wang and Thomas Shenk used allelic exchange to replace AD169’s
UL131 locus and flanking sequences with corresponding sequence from TR, a clinical
isolate. In so doing, they restored endothelial and epithelial tropism to the virus. They also
found that while the repaired virus (named BADrUL131-Y4) produced larger cell-free and
cell-associated virus progeny in epithelial and endothelial cells than its lab-adapted parent
(i.e., AD169), the amount of cell-free and cell-associated virus progeny produced from
fibroblasts had decreased up to 100-fold (113). Research has not yet exposed what the
selective advantage for deleterious mutations in the UL128-131 locus might be when viral
strains are serially passed in fibroblast culture. Other such mutations that impact
endothelial cell tropism have been discovered in the translocation of viral nucleic acid to
the nucleus (99, 101).

2.2 Antiviral Treatment
Today, there are four pharmaceuticals licensed for CMV treatment: ganciclovir
(Cytovene®, Roche) and its prodrug valganciclovir (Valcyte®, Roche), foscarnet
(Foscavir®, AstraZeneca), and cidofovir (Vistide®, Pharmacia) (94). Despite this, CMV
antiviral treatment is suboptimal due to toxicity, poor oral bioavailability, and resistance,
associated with all these drugs. While there are a number of candidate compounds in
development, only GW 1263W94 (Maribavir® or MBV, ViroPharma) has progressed as
far as phase III clinical trials.
Ganciclovir (GCV) was the first drug to be effective in patients with lifethreatening CMV infections (24) and the first to be specifically licensed for CMV
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treatment (94). Since the late 1980’s, GCV has become the treatment of choice for patients
who are immunocompromised (68). The compound is a nucleoside analog of guanosine
and a homolog of acyclovir, another successful anti-herpesvirus antiviral. As a nucleoside
analog, GCV acts as a competitive inhibitor of the viral DNA polymerase. Though it is not
an absolute chain terminator as acyclovir is, GCV slows the rate of DNA elongation and
thus inhibits viral replication. In vivo, GCV must be phosphorylated to its active
triphosphate form. This only occurs in virus-infected cells because the initial
phosphorylation step is performed by a viral kinase, pUL97. Once pUL97 protein
kinase/phosphotransferase phosphorylates GCV to its monophosphate form, cellular
kinases convert it to its active triphosphate form, which can then act to inhibit viral DNA
polymerase (24). Valganciclovir is a 1-valyl ester prodrug of GCV which dramatically
increases the oral bioavailability of GCV from 5.6% to 60.9% (48).
Due to their toxicity profiles, second line therapies are generally reserved except
when GCV is not an effective option, they include: foscarnet and cidofovir (35). Foscarnet
(trisodium phosphonoformate) is an inorganic pyrophosphate analog. The drug acts
directly on the viral DNA polymerase by noncompetitively binding its pyrophosphate
binding site. By binding this site, deoxynucleotide triphosphates (dNTPs) are unable to
bind the polymerase. Unlike GCV, foscarnet does not need to be phosphorylated for
antiviral activity (94). Cidofovir is another inhibitor of the CMV DNA polymerase. The
compound is an acyclic phosphonate nucleotide analog and, as it is administered in its
monophosphate form, it does not require initial phosphorylation by UL97 protein kinase to
have antiviral activity. Nevertheless, the monophosphate form does rely on cellular kinases
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in much the same way GCV does and ultimately acts on the CMV DNA polymerase in the
same manner (61, 94).
All of these drugs are associated with considerable toxicities. In
immunocompromised individuals, myelosuppression (e.g., granulocytopenia, anemia and
thrombocytopenia) by GCV can be the dose-limiting factor. While myelosuppression is of
lesser concern for foscarnet (and thus recommended for patients diagnosed with bone
marrow failure) (94), other toxicities, such as nephrotoxicity, electrolyte disturbances,
nausea, penile ulcerations, and seizures, make some physicians reticent to use foscarnet
except when necessary (46). Of the three, cidofovir may be the most toxic with side
effects such as: nephrotoxicity, neutropenia, ocular toxicity and metabolic acidosis. In
animal studies, the drug is both carcinogenic and teratogenic (94, 120).
Of the anti-CMV drugs on the horizon, MBV (5,6-dicholoro-2-(isopropylamino)1,-L-ribofuranosyl-1-H-benzimidazole, GW 1263W94, Maribavir®) is the most
promising and has come the closest of any to licensure (i.e., phase III clinical trials). MBV
comes from a class of new anit-CMV drugs called halogenated benzimidazole
ribonucleosides. They are characterized by a benzimidazole moiety halogenated with
chlorine or bromine, which substitutes for the purine base of the ribonuceloside. The
benzimidazole, which is the bicyclic fusion of benzene and imidazole, is typically
halogenated with elements such as chlorine or bromine. The sugar moiety can be derived
either from furanose (e.g., MBV) or pyranose and can either be a D- or L- isomer. Disomers of the halogenated benzimidazoles have been investigated for their anti“terminase” activity, preventing packaging of viral DNA into capsids. MBV, an L-
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isomer, appears to act by blocking the pUL97 viral kinase, thus inhbiting capsid egress
from the nucleus by a yet unknown mechanism.
The L-isomer halogenated benzimidazole ribonuceloside, MBV, is thought to act
on the viral kinase encoded by UL97 and potentially on the gene product of UL27, a
paralog of UL97. UL97 is an early/late tegument protein (69) known to autophosphorylate
serine and threonine residues at its amino-terminus (39) as well as the essential DNA
processivity subunit pUL44 (58), the RNA polymerase II carboxy-terminal domain (8),
and nucleoside analogs such as GCV. Structurally, pUL97 shares many typical protein
kinase motifs, however, overall the enzyme is relatively divergent from other herpesvirus
kinases (18, 58). Prichard et al. have done extensive work on the UL97 kinase. They found
that if they deleted a large portion of UL97 from a recombinant virus, the replication of the
virus was severely impaired and peak titers dropped as much as 100-fold (87). Researchers
working with similar null mutants have cataloged a number of viral defects that could shed
light on the function of pUL97, including: modestly reduced DNA synthesis, inefficient
DNA packaging (119), impaired nuclear egress (57, 119), and inappropriate aggregation
and sequestration of viral proteins into nuclear aggresomes (89). Recently, researchers
have suggested that pUL97 acts as a cellular CDK ortholog and induces cell cycle
progression through phosphorylation of the tumor-suppressor retinoblastoma protein (43).
MBV induces the phenotypic changes similar to pUL97 null mutants (43, 57, 58,
87, 89, 119). Mutant strains of CMV that are resistant to MBV have been isolated in cell
culture and the majority of their mutations are in the UL97 locus. However, some less
resistant mutants have been isolated with mutations mapped to the UL27 ORF (20, 55).
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UL27 may be a paralog of UL97 as it shares 12% amino acid identity (90). The in vivo
function of the UL27 protein is not known.
According to the ViroPharma Website and a Drugs in Research and Development
article, MBV is currently undergoing phase III clinical trials as a CMV prophylaxis in
transplant recipients. After being classified as an orphan drug, the Food and Drug
Administration (FDA) granted the drug fast-track status, whereby it has completed both
phase I and II clinical trials (1). Data from the phase II trials have not yet been published
but the phase I data on safety and pharmacokinetics in healthy and HIV infected subjects
are available. The latter demonstrate a favorable safety profile with good bioavailability
and relatively low toxicity (i.e., the most frequent adverse events were taste disturbance in
80% of subjects and headache in 53%) (115). Additional pharmacological studies provide
similar optimistic outlooks(56, 60) and in vitro studies further support the efficacy of the
drug (11, 117). Importantly, CMV strains which develop resistance to GCV, CDV, and
PFA appear to maintain sensitivity to MBV (11, 22).

2.3 Objectives
The tradition of culturing and studying CMV in fibroblasts has limited in vitro
testing of drug susceptibility to a clinically irrelevant cell type. The discovery that the
UL128-131 locus is essential for epithelial and endothelial entry has allowed us to repair
well-scrutinized strains of laboratory adapted virus and study them in more relevant cell
types. Certain clinical outcomes, such as the poor efficacy of front line drugs (e.g., GCV)
in treating CMV retinitis, suggest that infection of certain tissues is more resilient against
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our current repertoire of antiviral drugs. This study sought to test the in vitro activity of
two prominent anti-CMV drugs under epithelial cell culture conditions which had not
previously been explored. Our results demonstrate that there is a strong cell typedependence to the efficacy of GCV and MBV when tested in vitro. Both drugs tested were
more effective in fibroblast culture under conditions typically used to evaluate drugs.
Diminished efficacy in epithelial culture exposes how our current phenotypic assay of drug
susceptibility overlooks cell type differences that become critical to clinical treatment of
CMV disease. These results strongly advocate the use of multiple cell types when
assaying drug efficacy in vitro and shed light on possible reasons why these two drugs may
be limited in their current means of application.
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Chapter 3: Cell-Type Effect on Drug Susceptibility
3.1 Materials and Methods
Antiviral Compounds. Ganciclovir (GCV) was provided generously by Mark
Prichard while GW1263W94 (Maribavir®, MBV) was the generous gift from John Drach.
GCV was dissolved in 0.1 M sodium hydroxide. MBV was dissolved in anhydrous
dimethyl sulfoxide (DMSO).
Cells, Viruses, and Cell Culture Conditions. MRC-5 human fetal lung fibroblasts
(ATCC CCL-171) and human ARPE-19 retinal pigmented epithelial cells (ATCC CRL2302) were propagated in high glucose Dulbecco’s modified Eagle medium (Gibco-BRL)
supplemented with 10% fetal calf serum (HyClone Laboratories), 10,000 IU/L penicillin,
10 mg/L streptomycin (Gibco-BRL) (DMEM). An immortalized human embryonic lung
fibroblast cell line was established by transduction of primary cells with a defective
retrovirus that expresses human telomerase reverse transcriptase (13) and puromycin
resistance. The retrovirus was generated from plasmid pLPChTERT (Clontech), and cells
were infected as previously described (4). Transduced cells were selected by several
passages in media containing 1 g of puromycin (Sigma)/ml. Cells were maintained at
37°C and 5% CO2 in Dulbecco's modified Eagle medium-H with Gluta-max supplemented
with 10% fetal bovine serum and 1 g of puromycin/ml.

23
CMV strain BADrUL131-Y4 was derived from a bacterial artificial chromosome
(BAC) clone of the CMV strain AD169 genome that had been modified in E. coli by Wang
and Shenk to (1) contain a green fluorescent protein (GFP) reporter cassette to permit
efficient detection and quantitation of viral infection (112), and (2) to express a functional
UL131 protein, which permits efficient entry and replication in either ARPE-19 or MRC-5
cells (113). BADrUL131-Y4 was reconstituted by transfection of BAC DNA into ARPE19 cells as described (36) and amplified by passage exclusively in ARPE-19 cells. Tissue
culture supernatants (BADrUL131-Y4) were clarified by centrifugation, adjusted to 0.1 M
sucrose, aliquoted, and stored at –80°C. Viral titers of 1x105 (BADrUL131-Y4) were
determined by limiting dilution in 96-well plates (25) using MRC-5s. Stocks of
BADrUL131-Y4 were capable of entering ARPE-19 and MRC-5 cells with equal
efficiency.
Phenotypic Assay of Drug Susceptibility (Experiment 1). Two clear/flat-bottomed
96-well plates (Costar) each containing confluent MRC-5 or ARPE-19 cells were
uniformly infected with BADrUL131-Y4 for an average of 10 pfu/well and incubated for
one hour. Twelve three-fold dilutions of either GCV or MBV were prepared in triplicate in
a 96-well format. These drug dilutions were then transferred to infected cells to produce
final concentrations as follows: 320 M to 5.4x10-3 M GCV and a no-drug control; 100
M to 1.7x10-3 M MBV and a DMSO control of the same molarity as the highest MBV
concentration.
Plaque Reduction Assay. On day eleven, representative photos were taken of
plaque formation (indentified by GFP-expressing cells) using a Nikon 15 Diaphoto 300
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microscope equipped with a 470-525 nm UV filter. At each drug dilution, photos were
taken of plaques (more appropriately termed “foci” because the cells do not lyse) that
characterized the general size and morphology of the replicates. The following day, the
numbers of plaques formed in both the MRC-5 and ARPE-19 plates were counted. While
the total numbers of plaques were counted in each well of the MRC-5 plate, the ARPE-19
plate had smaller more abundant plaques. This made it impractical to read the total number
of plaques in each well. Instead, the densest area of plaque formation was found and the
maximum number of plaques that could be fit within the microscope’s viewer was read.
Several of these ARPE-19 wells were also counted in totality, as to provide a reference to
compare the cell types (Data presented on Plaque Formation Table).
GFP Fluorometry. GFP-fluorescence was measured using a PerkinElmer Victor2
1420 Multilable Counter plate reader with manufacturer provided fluorescence presets of
485/535nm wavelength (excitation/emission) for 0.1 second/well.
Yield Reduction Assay. As BADrUL131-Y4 forms plaques more slowly in MRC5 cells than in ARPE-19 cells, the yield reductions were conducted on the ARPE-19 plate
on day 19 and on the MRC-5 plate three days later on day 22. Fifty microliters of culture
medium were removed from each well and transferred to the bottom-edge row of a 96-well
plate filled with 200 µL/well of fresh medium (five-fold initial dilution). This row of 12
aliquots was then diluted vertically seven times with five-fold serial dilutions. Twohundred microliters of diluted supernatant were then transferred to a replicate plate
containing confluent cells. This procedure was repeated for all three replicates of each
drug group. Yield reductions of supernatants derived from an infected plate of a given cell
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type were carried out on a clear-walled/flat bottomed 96-well plate of the same cell-type
(e.g., viruses from ARPE-19 plates were titrated on ARPE-19 cells).
Titrations were read as soon as clear plaques had formed but before secondary
spread was suspected. For the ARPE-19 plates, this period was nine days after infection;
for the MRC-5 plates, it was 11 days after infection.
Comparison of Cell-Variant Entry. Each of five different cell-line variants was
seeded into a 96-well plate. Variants included high passage (hp, passage greater than 30),
low passage (lp, passage less than 20), and telomerase immortalized (hTERT, also hp) cell
variants of MRC-5 and ARPE-19 cell lines. The following cell variants were seeded in
duplicate eight-well columns: lp-ARPE-19, hp-ARPE-19, lp-MRC-5, hp-MRC-5, and
MRC-5 hTERT. Once all the cell monolayers were confluent, BADrUL131-Y4 was
titrated at 10-fold dilutions from 103pfu/mL to 10-3pfu/mL in each cell variant duplicate.
GFP-expressing cells were detected using a Nikon 15 Diaphoto 300 microscope equipped
with a 470-525 nm UV filter and viral plaques were counted in each titration at 24, 48, and
72 hpi.
Viral Growth Curves (Experiment 2). White-walled, clear/flat-bottomed 96-well
plates (Costar) were seeded with MRC-5 hTERT cells and eight identical plates were
seeded with hp-ARPE-19 cells. Once confluent, the plates were uniformly infected with
BADrUL131-Y4 at an MOI of about 0.02 and incubated for 12 hours. Plates were kept in
sealable plastic bags to prevent evaporation. In a 96-well format, ten three-fold dilutions
of either GCV or MBV were prepared in sextuplet using DMEM supplemented with 10%
FCS and PSG. Infected cell plates were aspirated to remove virus containing supernatant
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and washed twice with 200 µL/well phosphate buffered saline (PBS). Drug solutions were
then transferred to infected plates to produce final drug concentrations as follows: 320 M
to 4.9x10-2 M GCV and a no-drug control; 100 M to 1.5x10-2 M MBV, and DMSO
diluted appropriately to match the highest concentration of DMSO in MBV containing
cultures. In this manner, 24 replicates of each drug were generated per cell type. Note:
Titration of all culture supernatants, for the calculation of virus yield was performed on
MRC-5 hTERT cells, unlike in experiment 1.
Cytotoxicity Assays. Two white-walled, clear/flat bottomed 96-well plates (Costar)
were seeded with MRC-5 hTERT cells and two identical plates were seeded with hpARPE-19 cells. Each plate contained 12 replicates of the following treatment groups: each
of the three highest drug concentrations (i.e., 320 M, 107 M, and 36 M GCV or 100
M, 33 M, and 11 M MBV), cell controls without drug, and drug controls without cells
(i.e., 320 M GCV or 100 M MBV). Triplicates of each drug/cell-type combination (i.e.,
GCV on MRC-5 hTERT, GCV on hp-ARPE-19, MBV on MRC-5 hTERT, MBV on hpARPE-19) were assayed for cell viability using the promega CellTiter-Glo® kit (Promega).
CellTiter-Glo® uses an engineered luciferase reagent to quantify ATP in cell culture. ATP
concentration directly correlates with the number of viable cells in culture. Plates were
equilibrated to room temperature for 30 minutes. Using an Eppendorf epMotion 5070
Liquid Handling Workstation, 100 L media was removed from wells to be tested. One
hundred microliters of CellTiter-Glo® reagent was added to each well and the plates were
orbitally mixed for two minutes. The plates were then allowed to equilibrate for another
20 minutes before reading each well's luminescence using a PerkinElmer Victor2 1420
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Multilable Counter at manufacturer provided presets for 1.0 second/well readings. Mean
percent luminescence was calculated by dividing the luminescence of each drug treated
group by the luminescence of the no-drug control.
Statistics. Fifty percent inhibitory concentration (IC50) values were determined for
plaque reduction and GFP-fluorescence by plotting data against a log3 scale of drug
concentration. A four-parameter sigmoid line of best fit was determined using the Solver
function in Microsoft Excel. Each replicate's IC50 was obtained from the drug
concentration at the inflection point (mid-point) of this line. Yield reduction 90%
inhibitory concentration (IC90) values were calculated by normalizing data with a log10
transformation and then plotting this transformed data against a log3 scale of drug
concentration. The same four-parameter sigmoid line of best fit was determined using the
solver function in Microsoft Excel. Each replicate's IC90 was obtained from the drug
concentration that correlated with a log10 decrease in viral titer below the curve's upper
asymptote. The three replicate IC50s were then averaged and means ± one standard
deviation were presented in the text. Comparisons were made using the Browne-Forsythe
test of equal variance followed by the appropriate one-tailed t-test.

3.2 Results
The physiology of cells in the human body can be very diverse. Everything from
membrane receptor expression to the concentrations of important signalling molecules can
be profoundly cell-type dependent. The susceptibility of HCMV to GCV has only been
tested in fibroblast cells, which are physiologically distinct from more clinically relevant
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epithelial cells. The susceptibility of fibroblast and epithelial tropic BADrUL131-Y4 was
determined against serial dilutions of GCV in cell culture.
The three methods of quantifying viral replication had differing degrees of
sensitivity. The first method employed, plaque reduction, was generally effective, but
raised the concern that identification of plaques in two morphologically distinct cell types
was too subjective and could be easily biased. It was hoped that quantification of GFP
fluorescence might be a more objective means of measuring viral spread and yet not be so
laborious as yield reductions, but this method was found to lack sensitivity. Ultimately,
yield reductions proved to have the best combination of objectivity and sensitivity. Both
experiment 1 and experiment 2 have GCV and MBV components. The technical lessons
learned from the former were applied to the latter. The results for GCV will be presented
first (both experiment 1 and 2), followed by MBV (both experiment 1 and 2).
In the first experiment, representative photographs were taken to document the
morphology and nature of infection in each cell type: epithelial cells (ARPE-19) and
fibroblasts (MRC-5). Then all three methods (i.e., plaque reduction, GFP fluorescence,
and yield reduction) were tested to the effect of each drug on viral quantification.
Representative micrographs of cell infection and morphology. As shown in
Figure 1, representative micrographs were taken on day 11 to document the different cell
morphologies and the qualitative observation that drug susceptibility was not just
expressed as a reduction in viral plaques. The most striking observation was that treatment
of epithelial cells with either drug or fibroblasts with MBV, did not prevent GFP
expression in cells of primary infection. Only in fibroblasts treated with GCV did
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fluorescing cells dim and disappear. At high concentrations of drug, the great majority of
those cells, which were first to fluoresce green remained green throughout the experiment.
Unlike no-drug controls or lower drug concentrations, these cells that were green under
high GCV or MBV concentration did not spread from cell-to-cell laterally, nor did
secondary plaques appear, which form by virus release into the supernatant and infection
elsewhere in the cell monolayer. As the viewer scanned from high drug concentration
(Figure 1, A and C) to low drug concentration (Figure 1, B and D), single cells transitioned
to larger foci.
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Figure 1. Representative micrographs of infected cell cultures treated with serial dilutions
of ganciclovir (GCV). Photographs were taken 11 days post infection. (A) Infected
fibroblasts with 12 M GCV (higher concentrations were devoid of even singly infected
cells). Infected cells are isolated and do not form plaques. (B) Infected fibroblasts at the
lowest concentration of GCV (0.0054 M) are tightly clumped and form neat, laterally
expanding plaques that are randomly spaced across the monolayer. (C) Infected epithelial
cells at the highest concentration of GCV (320 M) are isolated and lateral spread
indicative of plaque formation does not occur. (D) Infected epithelial cells at lowest
concentration of GCV (0.0054 M) form large syncitial plaques, spaced uniformly across
the monolayer.
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GCV is not efficient at reducing plaques in epithelial cells. For quantitative
purposes of the plaque reduction assay, counting the number of viral foci, in contrast to
individual green cells, became critical. Although the unique morphology of each cell type
made this a dubious task, the fact that this particular strain of HCMV is highly fusogenic in
epithelial cells but not in fibroblasts was particularly problematic (113, 114). Therefore,
infected foci are easy to distinguish in fibroblasts but, in epithelial cells, a single large
fluorescing cell strongly resembles a green focus of cells that have fused (Figure 1).
On day 12, the number of plaques at each drug concentration was counted. These
data showed a drug-dependent change in green foci for both cell types. As shown in
Figure 2, a curve fitting program was used to find a sigmoid curve of best fit and a
concentration correlating with a 50% decrease in plaque formation (IC50). Data analysis
was performed by finding a line of best fit to each of the replicates, determining individual
IC50 concentrations and then averaging the IC50 values to give the averages and
corresponding standard deviations. The average fibroblast-IC50 was found to be 8 ± 3.7 M
GCV, while the average epithelial-IC50 was much higher at 100 ± 53 M GCV. These
data describe a 12-fold higher epithelial IC50 (p = 0.0412) and demonstrated that GCV is
much less effective at inhibiting plaque formation in epithelial cells.
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Figure 2. GCV inhibits plaque formation in fibroblasts more efficiently than in epithelial
cells. The figure presents one representative replicate of plaque reduction data from each
cell type fitted with a sigmoid curve. MRC-5 and ARPE-19 cell cultures were infected
with BADrUL131-Y4 at an MOI of 0.01 (10 pfu/well), in the presence of serial dilutions
of GCV at the concentrations indicated. On day 12, plaques were counted, graphed, and
curve fitted. Fibroblast- and epithelial-IC50s were calculated by finding the concentration
at the inflection point of the line. Since there were many more plaques in the ARPE-19
monolayers, these data represent the total number of plaques viewed in the microscope's
viewfinder at the most dense area of the well. Fibroblast data represent the total number of
plaques per well.
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Quantification of GFP fluorescence is inconclusive. As a more objective measure
of viral spread over the cell monolayer, GFP fluorescence was measured on day 19. The
data show a similar dose-dependency but neglected to capture the cell type effect that
could be observed under the microscope. Average fibroblast- and epithelial-IC50s were
calculated in the same manner as for plaque reduction, however, these calculations were
highly variable, even between replicates of the same cell type. A trend of low fibroblastIC50s and higher epithelial IC50s emerged, but no statistically significant difference was
detected between the cell types. One potential weakness of this experiment was the use of
clear-walled plates which may have permitted interwell cross-talk.
GCV inhibition of yield in fibroblasts is more complete than in epithelial cells.
Yield reduction, which evaluates the production of viral progeny by infected cells, may be
the most pertinent test of antiviral efficacy because it evaluates the cumulative effect of the
drug on the viral life cycle. To measure yield, cell-free supernatants were collected on day
19 (ARPE-19) or 22 (MRC-5) and titrated on the cell type from which they were
harvested. Titrations were read 9 (ARPE-19) or 11 (MRC-5) days post infection. Titers
were normalized using a log base 10 transformation and each replicate graphed against
concentration. A sigmoid curve was fitted to the data. IC90 (concentration of drug which
inhibits viral yield by 90%) values of each replicate were calculated by finding the
concentration at which virus titer dropped one log unit from the sigmoid curve’s upper
asymptote. The average fibroblast-IC90 was 1.3 ± 0.06 M GCV, while the average
epithelial-IC90 was over four-fold greater at 5.5 ± 1.51 M (p = 0.0417). Here, however,
IC90 calculations incompletely illustrate the difference in drug efficacy. GCV completely
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abolished new virus production in fibroblasts at a concentration of 4.0 M (Figure 3). In
contrast, the drug was incapable of completely eliminating production of new virus in
epithelial cells even at 40 M GCV (data from the highest drug concentration, 320 M,
was unusable because it succumbed to evaporation). This constituted as great as a 25-fold
difference in the GCV concentration that could abolish the production of viral progeny and
could account for the high incidence of CMV retinitis after GCV treatment.
Ensuring comparable entry between cell types. Another complication of the first
experiment was differential entry between the cell types. Observation of early GFP
expression suggested that the virus was not entering MRC-5 cells as quickly as ARPE-19
cells. There appeared to be more cells expressing green from primary infection in the
ARPE-19 cells than the MRC-5 cells. Passage of primary cells in culture can change their
physiology, so to see if a passage-dependent change in physiology was the reason for
differential entry, BADrUL131-Y4 was titrated on a number of passage variants of MRC-5
or ARPE-19 cells. These included high passage, low passage, and, in the case of the
MRC-5 cells, a high passage telomerase immortalized variant. High multiplicity of
infection wells showed comparable entry in all five cell-line variants after 24 hours.
Interestingly, after three days, the virus clearly showed higher (and more comparable)
infectivity in the high passage variants. These results suggested the use of high passage
ARPE-19 and MRC-5 hTERT cells for future study, so as to ensure comparable entry.
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Figure 3. GCV inhibits viral yield in fibroblasts more efficiently than in epithelial cells.
The figure presents one representative replicate of viral yield titers from each cell type
fitted with a sigmoid curve. MRC-5 and ARPE-19 cell cultures were infected with
BADrUL131-Y4 at an MOI of 1x105 (20 pfu/well), in the presence of serial dilutions of
GCV at the concentrations indicated. On day 19 (ARPE-19) and day 22 (MRC-5), culture
supernatants were titrated. Titers were graphed, and curve fitted. Fibroblast- and
epithelial-IC90s were calculated by finding the concentration of drug that correlated with a
log drop in viral yield from the upper asymptote.
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Growth curves show reduced GCV efficacy in epithelial cells (Experiment 2).
Experiment two incorporated growth curves to monitor the effect of the drug over time. It
followed a similar setup to the original design, but incorporated the aforementioned
changes (e.g., white-walled plates, excluding edge wells from design, etc.). Growth curves
showed how GCV impacted spread (quantified by GFP fluorescence) and virus yield over
time (Figures 4 and 5, respectively). GFP growth curves provided little useful data as to
the effect of cell type on GCV efficacy.
Viral yield growth curves portray highly divergent drug dynamics in each cell type.
In both epithelial and fibroblast cultures, the highest drug concentrations suppressed viral
titers to an undetectable level early on. In contrast, however, 12 M GCV was highly
effective in abolishing virus titers by nine days post infection (d.p.i) in fibroblast cells,
whereas virus from the epithelial cells treated with the same dose saw resurgence at 11
d.p.i. At even lower concentrations (e.g., 4.0 M), GCV appeared to be equally effective
at suppressing early virus production but again, at day nine, became highly ineffectual in
epithelial cells. At nine d.p.i., all of the epithelial virus titers began to rise at nearly
identical rates, apparently unperturbed by the antiviral drug.
When virus titers began to diverge, the epithelial-IC90 began to rise substantially
(see Table 1) and by 13 and 15 d.p.i., there was a significant difference between epithelial
and fibroblast IC90s (p = 0.0014 and p = 0.0007, respectively).
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Figure 4. GFP fluorescence does not unmask differential efficacy of GCV in fibroblasts
and epithelial cells. MRC-5 hTERT and ARPE-19 cells were infected with BADrUL131Y4 at an MOI of 0.02 in the presence of indicated concentrations of GCV. GFP
fluorescence was measured on the days indicated.
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Figure 5. Yield reductions illustrate the stark contrast of GCV efficacy in fibroblast and
epithelial cells. MRC-5 hTERT and ARPE-19 cells were infected with BADrUL131-Y4 at
an MOI of 0.02 in the presence of indicated concentrations of GCV. Supernatants were
removed and titered on MRC-5 hTERT cells on the days indicated.
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Table 1. GCV IC90s measured in MRC-5 and ARPE-19 cells.

Day b
9
11
13
15
a

ARPE-19
1.02
2.26
3.08
4.20

GCV IC90 a
MRC-5
±
0.396
1.25
1.403
1.14
0.429
0.83
0.454
0.84

E:F Ratio c
±
0.110
0.8
0.436
2.0
0.290
3.7
0.247
5.0

Average of three replicate IC90s.
Day post infection.
c The ratio of epithelial (E) IC
90 divided by the fibroblast (F) IC90.
* Rows that are bolded describe a statistically significant difference
between cell types ( = 0.05).
b
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MBV effectively inhibits plaque formation in fibroblast cells but poorly in
epithelial cells. Experiment one provided strong evidence for a cell type effect on the
efficacy of MBV in addition to GCV. This experiment tested GCV and MBV in parallel,
using identical designs. Here, the data pertaining to MBV plaque reductions are presented.
At the same time as GCV, MBV treated plates were photographed and plaques were
counted to determine whether MBV’s ability to inhibit plaque formation was at all affected
by cell type. Plaque reduction uncovered a seven-fold lower average fibroblast-IC50 than
epithelial-IC50, as depicted in Figure 6. With a fibroblast-IC50 of 2.4 ± 1.49 M and an
epithelial IC50 of 17 ± 5.6 M MBV (p = 0.00094), MBV was much better suited to inhibit
plaque formation in fibroblast culture than epithelial cell culture.
Just as in the component of experiment one dedicated to GCV susceptibility testing,
GFP fluorescence of MBV-treated cultures was inconclusive. Drug susceptibility curves
were highly variable and showed no significant shift in IC50 between cell types.
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Figure 6. MBV inhibits plaque formation in fibroblasts more efficiently than in epithelial
cells. The figure presents one representative replicate of plaque reduction data from each
cell type fitted with a sigmoid curve. MRC-5 and ARPE-19 cell cultures were infected
with BADrUL131-Y4 at an MOI of 1x105 (10 pfu/well), in the presence of serial dilutions
of GCV at the concentrations indicated. On day 12, plaques were counted, graphed, and
curve fitted. Fibroblast- and epithelial-IC50s were calculated by finding the concentration
at the inflection point of the line. Since there were many more plaques in the ARPE-19
monolayers, these data represent the total number of plaques viewed in the microscope's
viewfinder at the most dense area of the well. Fibroblast data represent the total number of
plaques per well.
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MBV does not block virus yield from epithelial cells. As in the initial GCV
experiments, the most compelling evidence that drug efficacy is cell type-dependent was
drawn from yield reduction data (Figure 7). The fibroblast-IC90 was found to be about
two-fold lower than the epithelial-IC90: 0.39 ± 0.002 M versus 0.95 ± 0.271 M,
respectively (p = 0.0354). Yet the IC90 does not properly convey the extent of this celltype disagreement. In this case, a qualitative analysis of the graphs is much more revealing.
The data show how MBV was capable of completely extinguishing production of
infectious virus in fibroblast cells at a concentration of 1.3 M, but even at the highest
concentration with reliable data (33 M because 100 M partially evaporated and data was
lost), 25 times more concentrated, it was unable to do the same in epithelial cells.
Referring to the plaque reductions above, we see that there were still green fluorescing
cells of both cell types at the highest concentrations of drug. In fibroblast culture in 0.41
M, these green foci were incapable of producing infectious virus, yet in epithelial culture
at 26-fold higher MBV concentrations, they were releasing sufficient virus to achieve a
titer of 10,000 infectious particles per mL.
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Figure 7. MBV efficiently inhibits viral yield in fibroblasts but is unable to do so at subcytotoxic doses in epithelial cells. The figure presents one representative replicate of viral
yield titers from each cell type fitted with a sigmoid curve. MRC-5 and ARPE-19 cell
cultures were infected with BADrUL131-Y4 at an MOI of 1x105 (20 pfu/well), in the
presence of serial dilutions of GCV at the concentrations indicated. On day 19 (ARPE-19)
and day 22 (MRC-5), culture supernatants were titered. Titers were graphed, and curve
fitted. Fibroblast- and epithelial-IC90s were calculated by finding the concentration of drug
that correlated with a log drop in viral yield from the upper asymptote.
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Growth curves show much greater MBV suppression of viral yield in fibroblasts
than epithelial cells (Experiment 2). Evaluating the efficacy of MBV in both cell-types
with growth curves clarified the time dimension of the observed effect. This phase
followed the same format as the GCV phase of experiment 2. Cell cultures were treated
with serial dilutions of MBV and both GFP fluorescence and virus yield titrations were
performed over a period of 15 days. Again, GFP fluorescence growth curves provided no
statistically significant evidence of cell type dependence of MBV activity (see Figure 8).
As in the first experiment with MBV, yield reductions were highly illustrative of
the reduced efficacy of MBV in epithelial as compared to fibroblast cells. As shown in
figure 9, the viral no-drug control group in both cell types reached about the same peak
titer at 15 days (105 pfu/mL), albeit at different rates. The most striking difference between
the two cell types was observed at the highest drug concentrations. In fibroblasts, the
highest MBV concentration (100M) effectively eliminated extracellular infectious virus.
Epithelial culture continued to produce sufficient viral progeny for an average extracellular
titer of 102 pfu/mL. The other treatment groups paralleled this finding. At drug
concentrations below 100 M, infected epithelial cultures scarcely dropped one log10
below the no-drug control titers, while virus propagation in fibroblasts was severely
curtailed above a concentration of 1.3 M MBV (exemplary replicate from day 11
displayed in Figure 10).
Calculated IC90s convey the cell-type divergence. This divergence could be
observed after nine d.p.i (Table 2). From day nine to fifteen, every epithelial-IC90 was
significantly higher than its fibroblast counterpart (highest p = 0.0001). Figure 9 shows
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how viral titers from the epithelial culture were inhibited only at cytotoxic levels of the
drug (100M). A more nuanced look at the epithelial data reveals a biphasic curve that
shows partial inhibition around the fibroblast-IC90 but then levels out (biphasic variation
cannot be captured by a sigmoid curve).
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Figure 8. GFP fluorescence does not unmask differential efficacy of MBV in fibroblasts
versus epithelial cells. MRC-5 hTERT and ARPE-19 cells were infected with
BADrUL131-Y4 at an MOI of 0.02 in the presence of indicated concentrations of MBV.
GFP fluorescence was measured on the days indicated.
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Figure 9. Yield reductions illustrate the stark contrast of MBV efficacy in fibroblast and
epithelial cells. MRC-5 hTERT and ARPE-19 cells were infected with BADrUL131-Y4 at
an MOI of 0.02 in the presence of indicated concentrations of GCV. Supernatants were
removed and tittered on MRC-5 hTERT cells on the days indicated.
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Table 2. MBV IC90s measured in MRC-5 and ARPE-19 cells.

Day b
9
11
13
15
a

ARPE-19
92.04
92.87
92.09
89.75

MBV IC90 a
±
MRC-5
2.774
0.26
2.011
0.29
1.588
0.35
1.764
0.45

±
0.142
0.148
0.187
0.453

E:F Ratio c
359.2
317.9
262.9
199.3

Average of three replicate IC90s.
Day post infection.
c The ratio of epithelial (E) IC
90 divided by the fibroblast (F) IC90.
* All rows show a statistically significant difference between cell types ( = 0.05).
b
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Figure 10. A cross-sectional view of viral yield curves shows that MBV efficiently
inhibits viral yield in fibroblasts but is unable to do so at sub-cytotoxic doses in epithelial
cells. The figure presents one representative replicate of day 11 viral titers from each cell
type fitted with a sigmoid curve. MRC-5 and ARPE-19 cell cultures were infected with
BADrUL131-Y4 at an MOI of 1x105 (20 pfu/well), in the presence of serial dilutions of
GCV at the concentrations indicated. Titers were graphed, and curve fitted. Fibroblastand epithelial-IC90s were calculated by finding the concentration of drug that correlated
with a log drop in viral yield from the upper asymptote.
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Both drugs show cytotoxicity at highest drug concentrations. To determine if a
component of the drug inhibition seen at high concentrations of GCV or MBV was due to
cytotoxic effects, a cell viability assay was performed. This assay reproduced the
conditions of the second experiment at the highest three drug concentrations with mock
infected cells. This was done in triplicate. The assay used to evaluate cell viability
quantifies the amount of ATP within cultured cells using a luciferase based reagent. At
nine, eleven, thirteen, and fifteen days post mock infection, cells were lysed, reagent
added, and luminescence was quantified. Luminescence data were used to calculate a
luminescence ratio. The luminescence produced by drug treated cells was divided by the
luminescence of untreated cells and presented as a percentage of the no-drug control. An
experimental group of the highest concentration of drug in cell-free media was also tested
to assure that neither drug would have a direct effect on the assay reagent. Luminescence
in this treatment group was never more than 2.5% of the no-drug control.
Raw luminescence decreased gradually in all the different treatment-cell groups
over the six days on which it was recorded. GCV did not show a noteworthy degree of
cytotoxicity in epithelial cells from days 9 to 15 (Figure 11). Fibroblasts, on the other
hand, reacted enigmatically to GCV (Figure 11). Luminescence of cells treated with any
of the three concentrations of GCV showed higher luminescence than their respective nodrug control, resulting in luminescence rising above 100%. The epithelial luminescence
ratio dropped to its lowest point (90%) on day 15 while fibroblast culture remained above
100% throughout. The peak luminescence ratio was 224% in fibroblast culture treated
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with 320 M GCV and measured on day 15. The dose dependency of this effect suggests
that it was a physiological change induced by the drug itself.
MBV showed similarly enigmatic results (Figure 12). Both cell types were
adversely affected by 100 M MBV on days 9 and 11, displaying a luminescence ratio of
about 78%. Other drug concentrations had proportionally lesser effects on ATP levels in
both cell-types. At later time points (i.e., days 13 and 15), the cells appeared to revcover.
MBV appeared to improve ATP maintenance in both epithelial and fibroblast culture,
although the effect was not as profound as in fibroblast culture treated with GCV. The
luminescence ratio peaked at 147% of the no-drug control on day 15 in fibroblast culture
treated with 33 M MBV.
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Figure 11. GCV's effect on cellular ATP levels. Epithelial (ARPE-19) and fibroblast
(MRC-5) cultures were treated with the three highest concentrations of GCV or no drug
and incubated for 9 to 15 days. At each time point, intracellular ATP in culture was
quantified using a luciferase-based assay. Luminescence is presented as a percent of the
no-drug control.
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Figure 12. MBV's effect on cellular ATP levels. Epithelial (ARPE-19) and fibroblast
(MRC-5) cultures were treated with the three highest concentrations of MBV or no drug
and incubated for 9 to 15 days. At each time point, intracellular ATP in culture was
quantified using a luciferase-based assay. Luminescence is presented as a percent of the
no-drug control.
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Discussion of Cell Type Specific Antiviral Drug Susceptibility
Historically, in vitro study of human cytomegalovirus (CMV) has been conducted
in fibroblast cell culture. Yet viral transmission and the serious pathologies associated
with CMV involve cell types other than fibroblasts in vivo. This unitary practice has lead
to the adoption of a series of laboratory-adapted strains of CMV that, in contrast to clinical
isolates, are no longer epithelial or endothelial tropic. The study of these laboratoryadapted viruses necessitates the use of fibroblast cell culture and therefore overlooks any
phenotypic differences in viral infection generated by clinically relevant cell types. The
discovery of a frameshift mutation in the UL131 locus that blocks the endothelial and
epithelial tropism of CMV strain AD169, and the repair of this mutation (BADrUL131Y4) has enabled the study of this virus in non-fibroblast cell cultures. It has also enabled
the phenotypic assessment of drug susceptibility in other cell types.
To our knowledge, no study has looked at the efficacy of either GCV or MBV in
parallel cell cultures of both fibroblasts and epithelial cells. The cell types chosen for this
study were based on precedent – MRC-5 fibroblasts are a common medium for the study
of CMV infection in vitro – and clinical relevance – ARPE-19 retinal pigmented epithelial
cells are associated with CMV retinitis. GCV, which is licensed for use by the Food and
Drug Administration (FDA), is the treatment of choice for cytomegalovirus infection and
disease. MBV is the most promising novel anti-CMV drug and the only anti-CMV drug in
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phase III clinical trials. Each has distinct targets. GCV, a nucleotide analog of guanosine,
targets the viral DNA polymerase and inhibits replication. MBV inhibits the viral gene
product of UL97 which appears to be a kinase intricately involved in viral egress from the
nucleus, as well as a number of other essential viral pathways.
Our results indicate that there is a cell type dependency to the antiviral activities of
both GCV and MBV in vitro. The mechanism of this cell type dependency has yet to be
discovered, but the implications of diminished efficacy of these drugs in epithelial cells are
broad.

4.1 Technical Obstacles
Preliminary studies can require a great deal of trial and error to refine a method that
optimizes sensitivity, reproducibility, and simplicity. A phenotypic drug susceptibility
assay for the two cell types was attempted multiple times, each time with greater
refinement. Some of the shortcomings of initial experiments have been described. For
example, in the first experiment, edge wells of each plate contained critical control
treatment groups and replicates. The long time course of the experiment combined with no
precaution to minimize evaporation adversely impacted data collection in these critical
wells, as virus grew poorly and cells appeared stressed. To avert this issue in later
experiments, we used sealable bags to minimize evaporation and avoided edge wells
entirely, taking all experimental data exclusively from interior wells. Another example was
the use of clear-walled plates in early experiments. Clear-walled plates allow fluorescence
leakage into neighboring wells. In instances where the two cell types showed equal total
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fluorescence, leakage would have affected cell type IC50 calculation uniformally.
Unfortunately, epithelial fluorescence typically surpassed fibroblast fluorescence, resulting
in greater leakage across wells of epithelial plates and an upward shift of those
fluorescence curves toward higher drug concentrations.
Overall, GFP proved to be a valuable method for quantifying primary infection
over a short time course, as was the case in our neutralizing studies. In contrast, where the
degree of viral spread was sought, GFP fluorescence did not seem to correlate as closely
with secondary plaque formation. This could be for a number of reasons. GFP has a
relatively long half life in mammalian cells (e.g., ~26 hours in mouse La-9 cells) (23) as
compared to other reporter genes such as luciferase. Protein half-lives are contingent on
rates of expression and degradation which could vary between cell types. If the kinetics of
expression-degradation were such that the former outweighed the latter, GFP
concentrations would increase overtime and those cells which were primarily infected
would contribute to a much greater percentage of the total fluorescence. In this scenario,
viral spread would be poorly quantified by GFP fluorescence. In contrast, reporter
fluorescence would correlate well with primary infection and stand as a very good
measurement tool. The latter scenario describes the use of GFP to quantify the relative
amount of virus entering cells. An analogy might be a pair of water hoses laying side by
side and gradually being turned on. If the two water flows are begun at different times and
the delay between them is great enough, the first will be producing so much water that the
observer may not even realize that the second is on. This dynamic is further complicated
by the use of multiple cell types which may have distinct expression-degradation kinetics.
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The GFP marker cassette of BADrUL131-Y4 is mediated by the simian virus 40 (SV40)
early promoter, which may even have different expression kinetics than CMV viral genes
such as IE-1 (113).

4.2 Possible Mechanisms of GCV Cell type-Dependent Susceptibility
Despite green fluorescence having significant drawbacks for the evaluation of drug
susceptibility, both plaque reduction and yield reduction analysis found a statistically
significant difference in GCV susceptibility. The average epithelial-IC50 by plaque
reduction was 12-fold higher than its fibroblast correlate. Similarly, yield reductions
exposed a five-fold higher epithelial-IC90 than fibroblast-IC90. Cytotoxicity experiments
failed to reveal underlying evidence of substantial cytotoxic effects, even at the highest
GCV concentrations. There are a number of different possible explanations for this
discrepancy.
The epithelial cells used here (ARPE-19) make up the outer component of the
blood-retinal barrier (BRB) of the eye. Retinal pigmented epithelial cells regulate a
number of physiological processes such as maintaining fluid and ion balance, transport of
nutrients and waste products between the retina and the choroid vascular system, and
preserving ocular homeostasis. The epithelium contains a number of transporters and
channels which facilitate this function. Many of these transporters may be involved in the
efflux of small molecules and pharmacological agents (65). A number of groups have
looked at the intravitreal kinetics of GCV and proposed that elimination of GCV from the
vitreous chamber probably involves some sort of active transport. Retention and
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infiltration of GCV into the retina is mediated first by uptake and second by efflux across
the BRB. A study investigating the activity of nucleobase and nucleoside transporters over
a five minute period, demonstrated that GCV uptake into human ARPE-19 cells is
primarily governed by passive diffusion (64).
On the other hand, there is evidence to suggest that mechanisms exist to expel GCV
from ARPE-19 cells via active transport. Multidrug resistance-associated proteins (MRP)
are members of the ATP-binding cassette (ABC) superfamily of membrane transporters.
This particular family of transporters has been extensively studied as organic anion drug
efflux pumps that are often upregulated in cancer cells (9). These pumps are naturally
found in a plethora of different cell types throughout the body. MRP4 (also known as
ABCC4) is a particular MRP that has been shown to efflux GCV and markedly increase
GCV resistance in herpes simplex virus thymidine kinase (HSV-TK) expressing cells that
over express the transporter (5). Recall that HSV-TK acts in the same way that CMV
UL97 does: activating GCV by monophosphorylation. Cells transfected with HSV-TK
activate GCV without CMV infection. Furthermore, MRP4 and related MRPs have been
detected by quantitative PCR in both flask and filter cultures of ARPE-19 cells, though to a
higher degree in the filter culture where cells differentiate and become polarized (110).
Although this same research has not been conducted in fibroblast cells, it is
reasonable to hypothesize that such cells, which do not perform the same protective
function as retinal epithelial cells, could express lower levels of MRPs and thus have a
muted mechanism of drug efflux. This could certainly explain the greater susceptibility of
these cells in culture. One might test this hypothesis by using antagonists of the major
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MRPs in both cell types and monitor the degree of synergism they show with GCV.
Knockout experiments could pinpoint more precisely the particular cellular genes involved
in drug efflux.
Another hypothesis might be that guanosine triphosphate concentrations might
differ between cell types. Nucleotide pools can vary appreciably depending on rates of
synthesis, degradation and even cell cycle (16, 103). A higher ratio of endogenous GTP to
GCV-triphosphate (GCV-TP) would competitively inhibit GCV incorporation into the
viral genome by the viral polymerase, leading to weaker antiviral activity. In addition to
differing levels of endogenous nucleotides, the metabolism of GCV could be different in
the two cell types. The intracellular half-life of (GCV-TP) in MRC-5 cells has been
estimated at roughly six (12) to 34 (102) hours depending on viral MOI. The data
presented here shows that the highest drug concentrations suppressed viral titers from both
cell types to a negligible level early in infection. In contrast, 12 M GCV was highly
effective in abolishing virus titers by nine days post infection (d.p.i) in fibroblast cells,
while virus in the parallel epithelial treatment group saw resurgence at the same time point.
If GCV were more quickly metabolized in epithelial cells, the drug might initially suppress
viral titers but not have the longevity that it shows in fibroblasts. Differential expression
of the protein kinases responsible for di- and tri-phosphorylation of GCV could be an
explanation for differential metabolism. To determine if endogenous nucleotide levels
were an influencing factor, nucleotide pools in the two cell types could be analyzed using
chromatographic methods. GCV-TP levels could be monitored using radioactively tagged
[H3]GCV-TP.
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4.3 Implications for a Cell type Difference in GCV efficacy.
Many methods of potentiating GCV activity are already being developed. The
physiological isolation of the retina is an impediment for treatment of a myriad of
vitreoretinal diseases. Proper delivery of pharmaceutical agents is paramount but
extraordinarily difficult because the blood retinal barrier (BRB) separates the vitreous and
retina from systemic circulation. A number of technologies have been developed to
overcome this barrier. Early in the AIDS epidemic, doctors attempted to inject GCV
directly into the vitreous of AIDS patients suffering from CMV retinitis (111). This was
not an attractive treatment, however, because of the highly invasive nature of intraocular
injections and because of the short half-life of GCV in the vitreous (7 hours) (63)
necessitated multiple injections. As a result, a host of intravitreal polymeric drug delivery
technologies are in development that prolong drug release and stabilize vitreal
concentrations. A review of these devices sheds light on their diversity and innovation
(121).
More recently, biochemists have attempted to exploit cellular amino acid
transporters for better GCV delivery. The GCV prodrug valganciclovir was engineered to
take advantage of one of these broad specificity transporters known as ABC0,+ (34). By
coupling an anionic amino acid to GCV in such a way that it will be cleaved later in
metabolism, researchers could trick the transporter into pumping prodrug across the
plasma membrane. This raises intracellular concentrations and improves drug efficacy.
ABC0,+ is found in a number of tissues, including the lung, colon, and eye. If the main
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obstacle to GCV activity in ARPE-19 cells is related to drug transport, such a prodrug
might add a productive compensatory mechanism.
Another method for potentiating GCV activity would be to exploit its competitive
relationship with guanosine triphosphate (GTP). By lowering endogenous
deoxynucleotide concentrations, one could increase the probability of GCV-TP
incorporation by the viral polymerase. One means of lowering nucleotide pools is to
inhibit the cellular ribonucleotide reductase responsible for reducing ribonucleotides to
deoxyribonucleotides. A number of different ribonucleotide reductase inhibitors have been
tested for the treatment of viral infections and cancer, including hydroxyurea (HU) and
mycophenolic acid (MPA). HU has been used in conjunction with anti-HIV nucleotide
analogs, in particular, didanosine (ddI) and adefovir, with great success (82). HU also
shows synergistic activity when combined with GCV in the treatment of other
herpesviruses and drug resistant viruses but has not been studied in treating CMV (76, 97).
MPA has been shown to have a similar synergistic potential when combined with GCV
(75).
In the clinic, cell type research is critically important. Before HAART, AIDS
patients in particular had a very high incidence of CMV retinitis. GCV was transiently
effective against the pathology but after a few months of treatment it would reappear. In
1996, a large multicenter retreatment trial was conducted that gave the median time for
CMV retinitis relapse as: 1.3 months for foscarnet treatment, 2.0 months for GCV
treatment, and 4.3 months for a GCV/foscarnet combination therapy (p < 0.001) (2). Other
indicators of morbidity and mortality were equally bleak. Fortunately, HAART became
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widely available that same year, bolstering patient cellular immunity and diminishing the
urgency felt to find better treatments for CMV retinitis. The results of our studies shed
light on why GCV may have been ineffectual in the eye, while effectively restricting CMV
disease in other tissues. Further study is necessary to optimize drug delivery and explore
possible synergistic combinations of GCV and other antiviral drugs.

4.4 Possible Mechanisms of MBV Cell type Dependent Susceptibility
To an even greater degree than GCV, MBV showed considerable cell typedependent susceptibility. A plaque reduction assay exposed a seven-fold higher epithelialIC50 than fibroblast-IC50 at a low MOI. Virus yield growth curves demonstrated an even
larger gap between epithelial-IC90 and fibroblast-IC90, as great as 200-350-fold. Except at
cytotoxic levels, MBV was essentially ineffective at blocking the generation of infectious
viral progeny in epithelial cells. Both cell types showed small amounts of cytotoxicity at
the highest drug concentration, but this could not account for the dramatic difference in
supernatant viral titers. Due to the still experimental status of MBV and the opacity of its
action, instructive hypotheses are tenuous at best.
MBV inhibits the viral protein kinase encoded by UL97. pUL97 has been proposed
as a cyclin-dependent kinase ortholog that is immune from normal cell cycle regulation
(43). As a result, pUL97 promotes cell cycle progression. The specific activities of the
UL97 kinase are still mysterious. It appears to phosphorylate retinoblastoma protein (Rb),
deactivating it (43). In normal cells, the Rb family of proteins binds E2F transcription
factors, thus blocking transcriptional activation of genes that induce cell cycle progression.
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pUL97 inhibition of this pathway coupled with modification of other cellular proteins by
viral enzymes such as pp71 (49), leads to unfettered cell cycle progression through G1/S
and G2/M checkpoints. The cumulative effect of CMV infection does not appear to
shorten the cell cycle but rather induces early transition into S phase, prolonged S and G2
phases, and ultimately metaphase arrest (45). Extrapolating simply from observations of a
phenotypic difference in cell growth, one might hypothesize that faster replicating ARPE19 cells might have less stringent cell cycle checkpoints.
A similar cell type-specific dynamic was elucidated from human lung bronchial
epithelial cells (BEC) in comparison to human lung fibroblasts (HLF). The study showed
that BECs were less susceptible to DNA-damage induced cell cycle arrest (33). Upon
insult of ionizing radiation and DNA-damage, HLFs became terminally trapped in G1
arrest. In contrast, BECs continued proliferating after transient G1 and G2 delays.
Additionally, radiation induced greater p53 and p21Cip1 increases in HLFs, while BECs
showed higher prexposure basal levels of p53. One might point out the fact that the lung
bronchial epithelium, while morphologically similar, is physiologically distinct from the
retinal pigmented epithelium. The lung bronchial epithelium is constantly bombarded by
DNA damaging reagents from noxious air pollution to endogenously produced defensive
agents (e.g., superoxide radicals). This is not the case for the retinal pigmented epithelium.
Nevertheless, cell type-specific cell cycle variations exist elsewhere. The literature is
plush with cell cycle research conducted in fibroblasts, yet there are examples that infer
cell cycle pathways from the study of other cell types. A study conducted in 2006 found
that the p16INK4a (p16) tumor suppressor gene plays fundamentally different roles in p53

64
regulation depending on the cell type (122). In human mammary epithelial cells, p16 was
found to inversely modulate p53 levels via an Rb-dependent mechanism. In contrast,
neither human mammary fibroblasts nor human foreskin fibroblasts displayed this
interdependence. Therefore, the potential for cell type-specific variations of cell cycle
pathways exist.
The cell type effect observed in the MBV experiments above could be attributed to
any number of cell cycle contributors. Recently, Chou et al recorded that MBV activity
was dependent on culture conditions (21). The group points out that widely differing
plaque reduction IC50s have been described in the literature without clarification (11, 117).
In their study, human foreskin fibroblasts exhibited a nearly 100-fold higher IC50 than
embryonic lung fibroblasts grown under the same conditions. They further demonstrated
that this gap could be virtually eliminated by adding a cellular kinase inhibitor (i.e.,
roscovitine, rapamycin, or LY294002) acting in a synergistic fashion with MBV.
Roscovitine is an oligo-specific cyclin-dependent kinase inhibitor; rapamycin is an
inhibitor of mTOR kinase, which is a regulator of protein translation; and LY294002 is an
inhibitor of phosphatidylinositol-3-kinase. All have activity against CMV infection (14,
47, 59) but there is no data, as of yet, that determines if these kinase inhibitors have an
effect directly on UL97 kinase function. These data posit the possibility that the cell type
difference may be due to differential expression of a cellular kinase that can substitute for
UL97 in MBV-treated ARPE-19 cells. Further study of the MBV-cellular kinase
relationship is needed. Any such study should evaluate both the synergistic effects of
combining different cellular kinase inhibitors with MBV and the effects, if any, of these
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kinase inhibitors directly on the UL97 kinase. This relationship will help tease out any
cellular kinases which may act as UL97 kinase surrogates.

4.5 Implications for a Cell type Difference in MBV efficacy.
Should our evidence prove to have significant clinical value, it might also support
more robust in vitro testing of drug susceptibility that incorporates multiple clinically
relevant cell types. Phenotypic assays of anti-CMV susceptibility should be performed in
endothelial and epithelial cells, which are central in CMV pathology. This is not to say
that data culled from fibroblasts is useless. In fact, clinical studies demonstrating a
significant anti-CMV activity of MBV reinforce this point. Fibroblasts may function well
as a neutral cell type control. In retrospect, MBV may have been abandoned and its
mechanism of action overlooked had it been tested in ARPE-19 cells exclusively. The use
of multiple, clinically relevant cell types to test the efficacy of antiviral drugs would be
optimum.
Despite the fact that MBV clinical trials have shown promising results, their design
is such that it would not have exposed the drug’s ostensive Achilles’ heel, proposed by our
study. Recently, data from a multicenter, randomized, double-blind, placebo-controlled,
dose ranging study of MBV in seropositive allogeneic stem-cell transplant recipients show
that MBV can have a moderate effect on preventing CMV infection (monitored by CMV
pp65 antigenemia and plasma DNA) compared with placebo (118). This study did not
evaluate the ability of the drug to treat CMV disease, but rather discontinued participation
at onset of CMV infection or disease. In addition, MBV displayed no evidence of
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myelosuppression, as existing first line anti-CMV therapies do (e.g., GCV). A similar
phase III clinical trial, which seeks to evaluate whether MBV prophylaxis leads to
significant reduction of CMV disease, is ongoing (118). However, this study was
conducted in transplant recipients and since CMV in transplant recipients manifests
infrequently in the eye (29) (these patients develop CMV disease more frequently in the
liver, gastrointestinal track, kidney, and lung) (31), the trial’s design was not likely to have
uncovered poor performance against retinal disease (which involves the retinal pigmented
epithelium). A phase I clinical trial was performed on HIV-infected men in 1996 to
evaluate the drug’s safety profile, but all of the subjects were stable and asymptomatic
(60). As of yet, MBV has not been assessed as a treatment for CMV retinitis. Even so, if
approved, physicians may elect to prescribe MBV to treat CMV retinitis. The data
presented herein may encourage the FDA to press for further testing or advise physicians
to use caution when considering the use of MBV for treating CMV retinitis.

The combined data from both these drugs begs another question: can they be used
together in combination therapy? In HIV therapy, the advent of the multidrug cocktail has
revolutionized treatment. Many propose that a similar approach is needed for CMV. Two
factors prevent this. First, all front line CMV antivirals have significant toxicity. GCV and
its prodrug are strong myelosuppressants and potent renal toxicity limits the use of both
cidofovir (CDV) and foscarnet (FOS). Second, all of these drugs have a common viral
target, the viral DNA polymerase. The success of HAART has been in its ability to
combine drugs with different targets to minimize the development of viral resistance. For
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these reasons, MBV is a highly anticipated drug and must be assayed with GCV, the
treatment of choice, to determine if there are drug interactions. A theoretical basis for
antagonism exists between these drugs. GCV’s activity depends on its phosphorylation by
the UL97 protein kinase, while MBV’s activity rests in its ability to inhibit this kinase.
The literature is currently divided on the subject of GCV-MBV antagonism. In 2002, an
article was published that found considerable synergy for combinations of MBV+CDV and
MBV+FOS, but MBV+GCV was only additive (not antagonistic) (30). A year later,
another study from the GlaxoSmithKline headquarters in North Carolina found the same
additive interaction (at this time, GlaxoSmithKline owned the rights to MBV) (96). In
2006, however, a group in Portland, Oregon, which has worked extensively with MBV,
found that MBV increased the GCV IC50 by 13-fold, a powerful antagonistic effect (19).
The same group had previously determined the effect of culture conditions on MBV
activity (21), which may influence the outcome of these assays. Today, the issue of GCVMBV antagonism remains unresolved, but data such as these caution the use of
GCV+MBV combination therapy in treating CMV of epithelial origin. Without
understanding the mechanism behind the cell type discrepancy uncovered by our study, it
is difficult to predict that MBV will not antagonize GCV because it has no activity in
retinal pigmented epithelial cells or rather that MBV has no activity against CMV in these
cells and combination therapy could potentially be even worse than GCV alone.
While these and other questions remained unresolved by this preliminary study of
cell type dependence. Our results warrant further in vitro testing and more critical clinical
trials to identify possible treatment concerns.
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